Evidence map›Paper›PMID 39656170›Full record

ArticleLiver international : official journal of the International Association for the Study of the Liver2025

Unsuccessful Direct Acting Antiviral Hepatitis C Treatment Among People With HIV: Findings From an International Cohort.

Brendan L Harney, Rachel Sacks-Davis, Daniela K van Santen, Ashleigh C Stewart, Gail V Matthews, Joanne M Carson, Marina B Klein, Karine Lacombe, Linda Wittkop, Dominque Salmon and 11 more

Abstract read
In one paragraph

Article in Liver international : official journal of the International Association for the Study of the Liver, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Brendan L HarneyDisease Elimination Program, Burnet Institute, Melbourne, Australia.ORCID 0000-0001-9288-6942
Rachel Sacks-DavisDisease Elimination Program, Burnet Institute, Melbourne, Australia.
Daniela K van SantenDisease Elimination Program, Burnet Institute, Melbourne, Australia.
Ashleigh C StewartDisease Elimination Program, Burnet Institute, Melbourne, Australia.
Gail V MatthewsThe Kirby Institute UNSW, Sydney, Australia.
Joanne M CarsonThe Kirby Institute UNSW, Sydney, Australia.
Marina B KleinDivision of Infectious Diseases and Chronic Viral Illness Service, Department of Medicine, McGill University Health Centre, Montreal, Canada.
Karine LacombeSorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Paris, France.
Linda WittkopCHU Bordeaux, Service d'information médicale, Bordeaux, France.
Dominque SalmonUniversité Paris Descartes, Service Maladies Infectieuses et Tropicales, AP-HP, Hôpital Cochin, Paris, France.
Olivier LeleuxUniversity of Bordeaux, INSERM, Bordeaux Population Health Research Centre U1219, CIC-EC, Bordeaux, France.
Laurence MerchadouUniversity of Bordeaux, INSERM, Bordeaux Population Health Research Centre U1219, CIC-EC, Bordeaux, France.
Marc van der ValkDepartment of Infectious Diseases, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.
Colette SmitStichting HIV Monitoring, Amsterdam, The Netherlands.
Maria PrinsDepartment of Infectious Diseases, Research and Prevention, Public Health Service of Amsterdam, Amsterdam, The Netherlands.
Anders BoydDepartment of Infectious Diseases, Research and Prevention, Public Health Service of Amsterdam, Amsterdam, The Netherlands.
Juan BerenguerCentro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.ORCID 0000-0001-8541-8200
Inmaculada JarrinCentro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.
Andri RauchDepartment of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Margaret E HellardDisease Elimination Program, Burnet Institute, Melbourne, Australia.
Joseph S DoyleDisease Elimination Program, Burnet Institute, Melbourne, Australia.

Funding

AbbVie BVAidsfonds 2008.026Aidsfonds 2013.037ANRS|MIEAustralian Department of HealthBristol-Myers-SquibbCentre for Infectious Disease Control of the National Institute for Public Health and the EnvironmentCHU de BordeauxCIHR CIHR FDN-143270CIHR Canadian HIV Trials Network CTN222Fonds de recherche du Québec-Santé (FRQ-S): Réseau SIDA/maladies infectieusesFrench National Agency for HIV and Hepatitis ResearchGileadGilead Sciences Netherlands BVInstituto de Salud Carlos III through the Red Temática de Investigación Cooperativa en Sida RD06/006Instituto de Salud Carlos III through the Red Temática de Investigación Cooperativa en Sida RD12/0017/0018Instituto de Salud Carlos III through the Red Temática de Investigación Cooperativa en Sida RD16/0002/0006ISCIII-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo RegionalNational Health and Medical Research CouncilResearch and Development Foundation of the Public Health Service of AmsterdamSaint-Antoine HospitalSHCS research foundationSwiss National Science Foundation 201369the Dutch Ministry of Health, Welfare and Sport
6 · The paper itself

Abstract

backgroundHistorically, hepatitis C virus (HCV) was difficult to treat among people with HIV. However, treatment with direct-acting antivirals (DAAs) results in 90%-95% of people being cured. There is a need to understand why a proportion of people are not cured. We aimed to examine characteristics that may indicate an increased probability of unsuccessful DAA HCV treatment.

methodsData were from the International Collaboration on Hepatitis C Elimination in HIV Cohorts. People who commenced DAA HCV treatment between 2014 and 2019 were included. Unsuccessful treatment was defined as a positive HCV RNA test at a person's first RNA test at least 4 weeks (SVR4+) following the end of treatment. Multivariable mixed-effects logistic regression was used to examine characteristics associated with unsuccessful treatment.

resultsOf 4468 people who commenced DAA treatment, 4098 (91.7%) had an SVR test 4+ weeks following the end of treatment, 207 (5%) of whom were unsuccessfully treated. Compared to a CD4+ cell count > 500 cells/mm

conclusionsThe overwhelming majority of people were successfully treated for HCV. Overall, 5% of those with an SVR4+ test were unsuccessfully treated; this was more likely among people with evidence of immunodeficiency and those who reported recently injecting drugs.

Indexed as

Antiviral AgentsHepacivirusHIV InfectionsTreatment FailureAdultCD4 Lymphocyte CountCohort StudiesCoinfectionFemaleHepatitis CHepatitis C, ChronicHumansLogistic ModelsMaleMiddle AgedRNA, ViralAntiviral AgentsRNA, Viralclinical researchdirect acting antiviralhepatitis CHIVtreatment

Identifiers

PMID39656170
PMCPMC11629931

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.